Alan L Kaganov Net Worth

The estimated Net Worth of Alan L Kaganov is at least $106 Mille dollars as of 23 August 2006. Alan Kaganov owns over 3,947 units of Atricure Inc stock worth over $106,174 and over the last 18 years Alan sold ATRC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alan Kaganov ATRC stock SEC Form 4 insiders trading

Alan has made over 1 trades of the Atricure Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Alan exercised 3,947 units of ATRC stock worth $2,250 on 23 August 2006.

The largest trade Alan's ever made was exercising 3,947 units of Atricure Inc stock on 23 August 2006 worth over $2,250. On average, Alan trades about 3,947 units every 0 days since 2006. As of 23 August 2006 Alan still owns at least 3,947 units of Atricure Inc stock.

You can see the complete history of Alan Kaganov stock trades at the bottom of the page.

What's Alan Kaganov's mailing address?

Alan's mailing address filed with the SEC is 2735 SAND HILL ROAD, , MENLO PARK, CA, 94025.

Insiders trading at Atricure Inc

Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie... e Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.

What does Atricure Inc do?

atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.

Complete history of Alan Kaganov stock trades at Atricure Inc

Atricure Inc executives and stock owners

Atricure Inc executives and other stock owners filed with the SEC include:

• Michael Carrel,
  President, Chief Executive Officer, Director
• Douglas Seith,
  Chief Operating Officer
• Salvatore Privitera,
  Chief Technology Officer
• Justin Noznesky,
  Senior Vice President, Marketing and Business Development
• Scott Drake,
  Independent Chairman of the Board
• Sven Wehrwein,
  Independent Director
• Mark Lanning,
  Independent Director
• B. Kristine Johnson,
  Independent Director
• Robert White,
  Independent Director
• Regina Groves,
  Independent Director
• Mark Collar,
  Independent Director
• Karen Prange,
  Independent Director
• Daniel Florin,
  Independent Director
• Angela Wirick,
  Chief Financial Officer
• Shlomo Nachman,
  Director
• Karen P Robards,
  Director
• Elizabeth D Krell,
  Director
• Richard M Johnston,
  Director
• Michael D Hooven,
  Director
• Andrew L Lux,
  V.P. & Chief Operating Officer
• Group I, Llc Murphy Michael...,
  
• M. Andrew Wade,
  CFO
• Tonya Austin,
  Chief Human Resources Officer
• Deborah L Morley,
  VP Clinical Affairs
• Lee R Wrubel,
  Director
• Maureen Shaffer,
  Vice President Marketing
• Jon A Sherman,
  VP Product Development
• Elsa Chi Abruzzo,
  VP; Regulatory&ClinicalAffairs
• Alan L Kaganov,
  Director
• Richard S Walsh,
  Vice President; Sales
• Management Group Viii L L C...,
  
• Management Group Viii L L C...,
  
• Stephen S Cambridge,
  Vice President; Sales
• Management Group Viii L L C...,
  
• Thomas J Etergino,
  Vice President and CFO
• Norman R Weldon,
  Director
• Patricia J Kennedy,
  VP, GM, International
• James L Lucky,
  VP; QA & Healthcare Compliance
• Management Group Viii L L C...,
  
• David J Drachman,
  President and CEO
• Richard Mcamden Partners St...,
  
• Richard Mcamden Partners St...,
  
• Donald C Harrison,
  Director
• Group I, Llc Donoghue Danie...,
  
• Stewart W Strong,
  Vice President US Sales
• Management Group Viii L L C...,
  
• Frederick Preiss,
  Vice President; Operations
• Julie A Piton,
  VP and CFO
• Deborah H Telman,
  Director
• Karl S. Dahlquist,
  Chief Legal Officer
• Vinayak Doraiswamy,
  Chief Scientific Officer
• Maggie Yuen,
  Director
• Deborah Lee Yount,
  Chief Human Resources Officer